104 related articles for article (PubMed ID: 20071790)
21. [Protein expression of Skp2 in osteosarcoma and its relation with prognosis].
Liao QD; Zhong D; Chen Q
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Jul; 33(7):606-11. PubMed ID: 18667774
[TBL] [Abstract][Full Text] [Related]
22. Expression and prognostic relevance of centromere protein A in primary osteosarcoma.
Gu XM; Fu J; Feng XJ; Huang X; Wang SM; Chen XF; Zhu MH; Zhang SH
Pathol Res Pract; 2014 Apr; 210(4):228-33. PubMed ID: 24440098
[TBL] [Abstract][Full Text] [Related]
23. May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol.
Serra M; Pasello M; Manara MC; Scotlandi K; Ferrari S; Bertoni F; Mercuri M; Alvegard TA; Picci P; Bacci G; Smeland S
Int J Oncol; 2006 Dec; 29(6):1459-68. PubMed ID: 17088985
[TBL] [Abstract][Full Text] [Related]
24. Growth patterns of osteosarcoma predict patient survival.
Kim MS; Lee SY; Cho WH; Song WS; Koh JS; Lee JA; Yoo JY; Shin DS; Jeon DG
Arch Orthop Trauma Surg; 2009 Sep; 129(9):1189-96. PubMed ID: 18682966
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma.
Kilpatrick SE; Geisinger KR; King TS; Sciarrotta J; Ward WG; Gold SH; Bos GD
Mod Pathol; 2001 Dec; 14(12):1277-83. PubMed ID: 11743051
[TBL] [Abstract][Full Text] [Related]
26. National Cancer Data Base report on osteosarcoma of the head and neck.
Smith RB; Apostolakis LW; Karnell LH; Koch BB; Robinson RA; Zhen W; Menck HR; Hoffman HT
Cancer; 2003 Oct; 98(8):1670-80. PubMed ID: 14534884
[TBL] [Abstract][Full Text] [Related]
27. Dynamic magnetic resonance imaging of regional contrast access as an additional prognostic factor in pediatric osteosarcoma.
Reddick WE; Wang S; Xiong X; Glass JO; Wu S; Kaste SC; Pratt CB; Meyer WH; Fletcher BD
Cancer; 2001 Jun; 91(12):2230-7. PubMed ID: 11413510
[TBL] [Abstract][Full Text] [Related]
28. The association of P-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma. A meta-analysis.
Pakos EE; Ioannidis JP
Cancer; 2003 Aug; 98(3):581-9. PubMed ID: 12879476
[TBL] [Abstract][Full Text] [Related]
29. Expression of platelet-derived growth factor-alpha receptor in human osteosarcoma is not a predictor of outcome.
Sulzbacher I; Birner P; Dominkus M; Pichlhofer B; Mazal PR
Pathology; 2010 Dec; 42(7):664-8. PubMed ID: 21080877
[TBL] [Abstract][Full Text] [Related]
30. Prognostic effect of diaphyseal location in osteosarcoma: a cohort case-control study at a single institute.
Kong CB; Kim MS; Lee SY; Cho WH; Song WS; Lee JA; Yoo JY; Chung SH; Jeon DG
Ann Surg Oncol; 2009 Nov; 16(11):3094-100. PubMed ID: 19697088
[TBL] [Abstract][Full Text] [Related]
31. Overexpression of hypoxia-inducible factor-1alpha in human osteosarcoma: correlation with clinicopathological parameters and survival outcome.
Yang QC; Zeng BF; Dong Y; Shi ZM; Jiang ZM; Huang J
Jpn J Clin Oncol; 2007 Feb; 37(2):127-34. PubMed ID: 17237146
[TBL] [Abstract][Full Text] [Related]
32. Immunoexpression of Ezrin and CD44 in patients with osteosarcoma.
Boldrini E; Peres SV; Morini S; de Camargo B
J Pediatr Hematol Oncol; 2010 Aug; 32(6):e213-7. PubMed ID: 20562647
[TBL] [Abstract][Full Text] [Related]
33. CD9 expression is not a prognostic factor in human osteosarcoma.
Kubista B; Erovic BM; Klinger H; Sulzbacher I; Trieb K
Cancer Lett; 2004 Jun; 209(1):105-10. PubMed ID: 15145525
[TBL] [Abstract][Full Text] [Related]
34. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma.
Mintz MB; Sowers R; Brown KM; Hilmer SC; Mazza B; Huvos AG; Meyers PA; Lafleur B; McDonough WS; Henry MM; Ramsey KE; Antonescu CR; Chen W; Healey JH; Daluski A; Berens ME; Macdonald TJ; Gorlick R; Stephan DA
Cancer Res; 2005 Mar; 65(5):1748-54. PubMed ID: 15753370
[TBL] [Abstract][Full Text] [Related]
35. [Prognostic factors for the local recurrence of osteosarcoma in extremities treated with combined therapy].
Zhang Q; Niu XH; Cai YB; Hao L; Ding Y
Zhonghua Wai Ke Za Zhi; 2007 Aug; 45(16):1114-7. PubMed ID: 18005614
[TBL] [Abstract][Full Text] [Related]
36. Expression of transforming growth factor-beta (TGF-beta) isoforms in osteosarcomas: TGF-beta3 is related to disease progression.
Kloen P; Gebhardt MC; Perez-Atayde A; Rosenberg AE; Springfield DS; Gold LI; Mankin HJ
Cancer; 1997 Dec; 80(12):2230-9. PubMed ID: 9404699
[TBL] [Abstract][Full Text] [Related]
37. Treatment algorithm for locally recurrent osteosarcoma based on local disease-free interval and the presence of lung metastasis.
Nathan SS; Gorlick R; Bukata S; Chou A; Morris CD; Boland PJ; Huvos AG; Meyers PA; Healey JH
Cancer; 2006 Oct; 107(7):1607-16. PubMed ID: 16933325
[TBL] [Abstract][Full Text] [Related]
38. Tumor necrosis in pediatric osteosarcoma: impact of modern therapies.
Hendershot E; Pappo A; Malkin D; Sung L
J Pediatr Oncol Nurs; 2006; 23(4):176-81. PubMed ID: 16766682
[TBL] [Abstract][Full Text] [Related]
39. P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy.
Baldini N; Scotlandi K; Serra M; Picci P; Bacci G; Sottili S; Campanacci M
J Orthop Res; 1999 Sep; 17(5):629-32. PubMed ID: 10569469
[TBL] [Abstract][Full Text] [Related]
40. Prognostic relevance of increased angiogenesis in osteosarcoma.
Kreuter M; Bieker R; Bielack SS; Auras T; Buerger H; Gosheger G; Jurgens H; Berdel WE; Mesters RM
Clin Cancer Res; 2004 Dec; 10(24):8531-7. PubMed ID: 15623635
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
